Rockwell Medical Announces Proposed Public Offering of Common Stock
June 17 2019 - 4:01PM
Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the
“Company”), a biopharmaceutical company dedicated to improving
outcomes for patients with anemia, with an initial focus on
end-stage renal disease (ESRD) and chronic kidney disease (CKD),
today announced that it has commenced an underwritten public
offering of its common stock. All of the shares of common
stock to be sold in the offering will be offered by Rockwell
Medical. In addition, Rockwell Medical intends to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the shares of its common stock at the public offering price less
the underwriting discount. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering. Rockwell Medical anticipates using the
net proceeds from the offering for the commercialization of
Dialysate Triferic and I.V. Triferic, research and development and
general corporate purposes.
Piper Jaffray & Co. and Cantor Fitzgerald & Co. are
acting as book-running managers for the offering.
The securities described above are being offered by Rockwell
Medical pursuant to a shelf registration statement previously filed
with and declared effective by the Securities and Exchange
Commission (the “SEC”). A preliminary prospectus supplement
related to the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to this offering may be obtained, when available,
from: Piper Jaffray & Co., Attn: Prospectus Department,
800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at
(800) 747-3924, or by email at prospectus@pjc.com; or Cantor
Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th
floor, New York, NY 10022; Email: prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company dedicated to
improving outcomes for patients with anemia, with an initial focus
on end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Rockwell Medical’s exclusive renal drug therapy, Triferic, supports
disease management initiatives to improve the quality of life and
care of dialysis patients and is intended to deliver safe and
effective therapy, while decreasing drug administration costs and
improving patient convenience. The Company has developed multiple
formulations of Triferic, the only FDA-approved therapeutic
indicated for iron replacement and maintenance of hemoglobin in
hemodialysis patients. The Company’s strategy is to bring its
therapeutics to market in the United States and to utilize partners
to develop and commercialize such therapeutics in international
markets. Rockwell Medical is also an established manufacturer,
supplier and leader in delivering high-quality hemodialysis
concentrates/dialysates to dialysis providers and distributors in
the U.S. and abroad.
Forward Looking Statements
Certain statements in this press release may constitute
“forward-looking statements” within the meaning of the federal
securities laws, including, but not limited to, Rockwell Medical’s
expectations regarding the consummation of the offering, the terms
of the offering, and the satisfaction of customary closing
conditions with respect to the offering and the anticipated use of
the net proceeds of the offering. Words such as “may,” “might,”
“will,” “should,” “believe,” “expect,” “anticipate,” “estimate,”
“continue,” “could,” “plan,” “potential,” “predict,” “forecast,”
“project,” “plan”, “intend” or similar expressions, or statements
regarding intent, belief, or current expectations, are
forward-looking statements. While Rockwell Medical believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties
(including, without limitation, those set forth in Rockwell
Medical’s SEC filings), many of which are beyond our control and
subject to change. Actual results could be materially different.
Risks and uncertainties include: changes as a result of market
conditions or for other reasons, the risk that the offering will
not be consummated, and the impact of general economic, industrial
or political conditions in the United States or internationally, as
well as those risks more fully discussed in Rockwell Medical’s SEC
filings. Accordingly, you should not place undue reliance on these
forward-looking statements. Rockwell Medical expressly disclaims
any obligation to update or alter any statements whether as a
result of new information, future events or otherwise, except as
required by law.
Triferic® is a registered trademark of Rockwell Medical,
Inc.
Contact
Investor Relations:Lisa M. Wilson, In-Site Communications,
Inc.T: 212-452-2793E: lwilson@insitecony.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Sep 2023 to Sep 2024